Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
What Is the What "we really hadn’t decided whether I was just helping Valentino write his own book, or if I was writing a book about him." Valentino points out that, "I thought I might want to write my own book, but I learned that I was not ready to do this. I was still taking classes in basic writing at Georgia Perimeter College." Dave Eggers discusses the difficulties in writing a book of this nature: "For a long while there, we continued doing interviews, and I gathered the material. But all along, I really didn’t know exactly what form it would finally take—whether